





PubMed	Nucleo	tide	Protein	Genome	Structure	PopSet	Taxonomy	OMIMO
Search Publ	vled 1	for					Go	Clear
***************************************			Limits	Preview/Ir	ndex Hi	story	Clipboard	Deta
•		Disp	lay Abstra	ct 🔽	Sort 🔻	Save Text	Clip Add	Order

		771.	I Infact Dis	1088 April	57(1):655-62	Polot	ad Articlas Bas	ka LinkOut

Entrez PubMed

J Intect Dis 1988 Apr; 15/(4):055-02

Attenuation of bovine parainfluenza virus type 3 in nonhuman primates and its ability to confer immunity to human parainfluenza virus type 3 challenge.

PubMed Services


van Wyke Coelingh KL, Winter CC, Tierney EL, London WT, Murphy BR.

Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland 20892.

Related Resources

Bovine parainfluenza virus type 3 (PIV-3) was evaluated as a candidate live-virus vaccine to protect against infection with human PIV-3. The level of replication of bovine and human PIV-3 and the efficacy of immunization with bovine PIV-3 in protecting against subsequent challenge with human PIV-3 was evaluated in nonhuman primates. The duration and magnitude of replication of human and bovine PIV-3 in the upper and lower respiratory tracts of New World monkeys was similar. and animals infected with bovine PIV-3 developed resistance to challenge with human PIV-3. The replication of two bovine strains of PIV-3 was restricted 100- to 1000-fold in Old World primates but was sufficient to induce high levels of neutralizing antibody to human PIV-3. The combined properties of restricted replication and induction of a protective immune response to human PIV-3 in nonhuman primates make bovine PIV-3 a promising candidate for a live-virus vaccine to protect humans against disease caused by PIV-3.

PMID: 2831282 [PubMed - indexed for MEDLINE]



Write to the Help Desk NCBI | NLM | NIH **Department of Health & Human Services**